Cantor Fitzgerald analyst Sarah James lowered the firm’s price target on Teladoc (TDOC) to $10 from $12 and keeps an Overweight rating on the shares. Teladoc’s long-term growth in BetterHelp is heavily levered towards insurance coverage, but there are more pathways to sustainable growth in Integrated Care, the analyst tells investors in a research note. The firm believes more proof is needed on a return to revenue growth in BetterHelp before the multiple lifts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc’s Strategic Shift and Competitive Pressures Lead to Hold Rating
- Cautious Hold on Teladoc Amid Competitive Pressures and Strategic Risks
- Teladoc Health Reports Q2 2025 Earnings
- Teladoc’s Mixed Performance: Strong IC Growth Overshadowed by BH Segment Uncertainty Leading to Hold Rating
- Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports